H igh-dose chemotherapy, wholebody radiation, or radiation to the gonads can cause permanent infertility (1) . This is a significant human health concern because over 75,000 people under the age of 40 in the United States are diagnosed with cancer each year and most are cured (2) . Thus, cancer patients can look beyond their diagnosis and treatment to quality of life after cancer. Parenthood is important to cancer survivors, and distress over infertility can have long-term psychological and relationship implications (3) . Therefore, the American Society for Clinical Oncology (ASCO) (4) and the American Society for Reproductive Medicine Ethics Committee (5) recommend that the reproductive risks of gonadotoxic therapies and options for preserving fertility be discussed with patients before initiating treatment. While adoption and third-party reproduction provide alternative family-building options, the available data indicate that most cancer survivors prefer to have their own biological children (4) .
Postpubertal adolescent and adult males have the option to cryopreserve sperm before oncological treatment ( Fig. 1, top) . This is a simple and established method for preserving fertility potential and allows men to father their own genetic children. Nearly 17,000 men between the ages of 15 and 44 are diagnosed with cancer each year in the United States, and nearly 2,385 survivors will receive a treatment that puts them at high risk of azoospermia (2, 6) . Unfortunately, only about 24% of men in this age range cryopreserve semen before their oncological treatment (7) . Therefore, we calculate that each year in the United States, over 1,800 adult cancer survivors will be infertile with azoospermia and have limited options to have their own biological children because they did not save a semen sample. In some cases, sperm can be recovered surgically from small focal areas of spermatogenesis in the testes using the testicular sperm extraction method and can be used to fertilize oocytes by intracytoplasmic sperm injection (ICSI) (8) .
There are no options to preserve the fertility of prepubertal boys, who are not yet making sperm. This is a significant problem because about 5,131 boys under the age of 15 in the United States are expected to develop cancer each year and 83% are expected to survive (2) . A report from the Childhood Cancer Survivor Study indicates that the cytotoxic therapies for cancer reduce the number of young men subsequently able to have children by 44% (6, 9) . Based on these statistics, we calculate that each year in the United States, 1,874 young male cancer patients will become sterile owing to their treatment. In addition to cancer survivors, over 500 patients under the age of 20 receive hematopoietic stem cell transplants each year in the United States for nonmalignant conditions (e.g., bone marrow failure, blood and immune deficiencies, autoimmune disorders) (10) . Myeloablative conditioning therapy before bone marrow transplantation is associated with a high risk of infertility (4, 9, 11, 12) . The ASCO report notes that ''Impaired future fertility is difficult for children to understand, but potentially traumatic to them as adults'' (4) . The available data indicate that greater than 80% of parents consented to fertility preservation procedures on behalf of their children before initiation of gonadotoxic therapies (13, 14) .
The summed incidence of chemotherapy or radiationinduced male factor infertility that cannot be treated with existing reproductive therapies is approximately 4,000 individuals each year in the United States. Therefore, responsible development of novel therapies to help these patients have biological children has a significant potential impact.
Promising results in animal models and human cell lines (Fig. 1, bottom) have generated enthusiasm that stem cells might be used or manipulated to preserve and/or restore the fertility of patients who are not producing sperm and have no other options to protect their future fertility before receiving gonadotoxic chemotherapy or radiation treatments . We will review the methods of spermatogonial stem cell (SSC) transplantation (Fig. 1, blue boxes) , testicular tissue grafting, testicular tissue organ culture (Fig. 1, orange boxes) , and induced pluripotent stem cell differentiation into gametes or transplantable male germ line stem cells (Fig. 1, red boxes) . Table 1 summarizes published reports detailing the progress of each method. Enthusiasm for these experimental stem cell technologies is tempered by concerns about feasibility and safety, particularly for the vulnerable prepubertal
FIGURE 1
Standard and experimental options for preserving male fertility. Top, sperm obtained by ejaculation or surgical retrieval from the testes or epididymides are competent to fertilize oocytes using assisted reproductive techniques including IUI, IVF, or IVF ICSI that are standard in most fertility clinics. These options are not available to prepubertal boys who are not producing sperm or to adult azoospermic men. Bottom, testis tissue obtained via biopsy from prepubertal boys contains spermatogonial stem cells (SSCs) that can produce sperm in the context of the intact tissue by xenotransplant, organ culture, or autologous transplantation back into the individual (orange boxes). Sperm retrieved from cultured or transplanted tissue can be used for ICSI. Cells in suspension obtained from biopsied testicular tissue can be transplanted back into the endogenous seminiferous tubules of the patient (blue boxes). SSCs in the suspension can regenerate spermatogenesis and, in some cases, fertility. For infertile individuals who did not preserve germ cells before gonadotoxic therapy, iPSCs may be produced from their somatic cells (e.g., skin or blood) to differentiate into transplantable germ cells (primordial germ cells [PGCs] or SSCs) or haploid germ cells that can be used for ICSI (red boxes). Excerpted with permission from Clark AT, Phillips BT, Orwig KE, Nat Med 2000;1564-5. patient population (14, (35) (36) (37) . Questions about feasibility stem from the early stage of technology development, uncertainty about optimal freezing conditions, concerns that a small testicular biopsy will contain few stem cells, and the lack of culture conditions to expand human germ line stem cells. Questions about safety are associated with the risks of surgery to obtain testicular tissue and the potential for malignant contamination in transplanted cells or tissue. Nonetheless, academic centers around the world are already cryopreserving testicular tissues for prepubertal boys and men in anticipation that stem cells in that tissue can be used safely and effectively to restore future fertility (13, 16, 21, (38) (39) (40) (41) .
SSCs AND SPERMATOGENESIS
SSCs are the adult tissue stem cells in the testes that balance self-renewing and differentiating divisions to maintain continuous sperm production throughout the postpubertal life of men. SSCs are rare cells located on the basement membrane of seminiferous tubules ( Fig. 2A and B) . These stem cells give rise to undifferentiated progenitor spermatogonia that undergo several transit-amplifying mitotic divisions, followed by two meiotic divisions and morphological differentiation to produce sperm. Spermatogenesis is an extraordinarily productive system that produces approximately 40 million sperm per gram of tissue per day in mice (42) and 5.5 million sperm per gram of tissue per day in men (43) . The difference in sperm production in mice and men can be explained in part by differences in the number of transitamplifying mitotic divisions that precede meiosis (44) . In humans, the SSC pool is composed of A dark and A pale spermatogonia. A dark are relatively quiescent, while A pale are mitotically active and undergo one to two transitamplifying divisions before giving rise to differentiating type B spermatogonia and then primary spermatocytes, which enter meiosis and migrate off the basement membrane of the seminiferous tubule ( Fig. 2B and C) . Owing to its highly proliferative nature, the spermatogenic system is an unintended target of chemo-and radiotherapies. The relative effects of various chemo-and radiotherapy regimens on male fertility are detailed in several previous reports (9, 11, 19, 45, 46) . The extent that the fertility of a patient is affected depends on the dose, type, and frequency of treatment (1) . There has been significant progress in minimizing the unwanted side effects of the cancer treatment by adjusting and modifying the therapeutic regimens without compromising the efficiency of oncological treatments (47) . Nonetheless, some cancer treatments, like whole-body radiation, radiation to the gonads, and alkylating chemotherapy, can be particularly gonadotoxic and result in prolonged or permanent azoospermia. In the following sections, we will review experimental stem cell-based approaches that may have application for preserving and/or restoring male fertility.
SSC TRANSPLANTATION
Brinster and colleagues pioneered the technique for SSC transplantation in mice in 1994, demonstrating that donor SSCs could engraft the seminiferous tubules of chemotherapy-treated recipient mice and regenerate spermatogenesis and fertility leading to the production of viable progeny through normal breeding (31, 31) . The SSC transplantation technique has become the experimental gold standard for quantifying stem cell activity and may have application for treating male factor infertility. Homologous species SSC transplantation has now been reported in mice, rats, pigs, goats, bulls, sheep, dogs, and monkeys, including the production of donor-derived progeny in mice, rats, goats, and sheep (29, (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) . SSCs from donors of all ages, newborn to adult, can regenerate spermatogenesis (49, 62) , and SSCs can be cryopreserved and retain spermatogenic function upon thawing and transplantation (29, 63, 64) . We recently demonstrated that SSCs from the testes of prepubertal and adult rhesus macaques could be frozen, thawed, and transplanted to regenerate spermatogenesis and produce fertilization-competent sperm (29, 59 ). Progress in these previous studies suggests that it should be feasible for prepubertal boys or adult men to cryopreserve testicular tissue containing SSCs before treatment and have these cells reintroduced into their testes at a later date to regenerate spermatogenesis. Radford and colleagues initially introduced the autologous SSC transplantation technique to the human clinic in 1999 (65) . In Manchester, United Kingdom, testicular tissue from 12 male non-Hodgkin's lymphoma patients was cryopreserved as a cell suspension before the initiation of chemotherapy. At later dates, seven of the patients had the cells injected back into their testes (66, 67) . To our knowledge, there have been no follow-up reports on the fertility status of those patients so the outcome of the experiment is unknown. Even if the men in that study fathered children, it would be difficult to demonstrate unequivocally (in the absence of a unique genetic marker) that those offspring resulted from sperm produced by transplanted stem cells rather than from surviving endogenous stem cells. There have been no subsequent reports of SSC transplantation in humans since the 1999 study. Nonetheless, this bold, pioneering study demonstrated that patients are willing to pursue experimental stem cell approaches to achieve fertility (65, 67) . To date, published reports indicate that testicular tissue or cells have been cryopreserved for more than 150 prepubertal and adult male patients worldwide, and this is likely an underestimate of actual cases (13, 14, 21, 38-41, 65, 67) .
For SSC transplantation in rodents, the testes are typically accessed via a midventral abdominal incision. Testicular cells (including SSCs) are injected using a pulled glass capillary pipette inserted via the efferent ducts into the rete testis space, which can be visualized on the surface of the testis and is contiguous with all seminiferous tubules (68) . Testis anatomy in larger animals, including nonhuman primates and humans, is different than that in rodents, with the rete testis being centrally located in the testes. Schlatt and colleagues (69) demonstrated that ultrasound can be used to visualize the rete testis and guide an injection needle into the rete testis space. Ultrasound-guided rete testis injection has now been used for SSC transplantation in several large animals species, including nonhuman primates (29, (52) (53) (54) (55) (56) (59) (60) (61) . For this approach, an injection needle is simply inserted under ultrasound guidance through the scrotal skin and testicular parenchyma into the rete testis space ( Fig. 3 depicts an example from nonhuman primates) (29) .
Clinical translation of the SSC transplantation technique appears imminent considering successes in several large animal models (Table 1) and that many patients have already cryopreserved testicular tissue or cells. However, several questions and/or challenges remain. First, the small amount of tissue that can be obtained from testicular biopsies (especially from prepubertal boys) may contain a relatively small number of stem cells. Second, in the cancer survivor paradigm, it is essential to eliminate the risk of reintroducing malignant cells. The sections below describe approaches that may circumvent these two challenges. A third challenge for translating new stem cell technologies to the clinic is the limited availability of reagents and experimental tools for studying humans SSCs.
SSC CULTURE
In rodents, SSCs can be greatly expanded in culture and maintain competence to generate spermatogenesis and restore fertility upon transplantation (57, 58, 70, 71) . Several groups
FIGURE 3
Ultrasound-guided rete testis injections. For SSC transplantation into larger animals, including nonhuman primates, ultrasound is used to visualize the rete testis (echo-dense structure) (A). (B and C) The injection needle is inserted under ultrasound guidance through the scrotal skin into the rete testis space, which is continuous with the seminiferous tubules. (C) Positive pressure is applied so the cells are slowly injected into the rete testis space and seminiferous tubules.
have reported extending SSC culture to large animal species (72) (73) (74) (75) (76) . This approach could theoretically be employed to amplify the small number of stem cells that can be obtained from a biopsy and also to demonstrate the absence of malignant contamination. A number of laboratories have reported culturing human SSCs (21, 38, (77) (78) (79) (80) (81) (82) , including three from the testes of prepubertal patients (38, 78, 80) . These human tissue studies are promising but challenged by the inability to evaluate the full spermatogenic potential of cultured cells by homologous species transplantation into human testes. To date, each laboratory has used a different approach to culture human SSCs and different methods to assess outcomes. These published human SSC culture results need to be replicated in other laboratories and evaluated using robust markers of human spermatogonia and by xenotransplantation to nude mice (see section below on experimental methods to track human germ line stem cells).
In a recent study, Elhija and colleagues reported that testicular cells from 7-day-old immature mice could be expanded in a three-dimensional soft agar culture system and differentiated to produce postmeiotic germ cells, including morphologically normal sperm (83) . Additional studies are needed to confirm that the resulting sperm are functionally competent to fertilize mouse oocytes. If a similar approach is successful in humans, this would eliminate the need to put cells back into the patient and thus the risk of reintroducing malignant cells into a cancer survivor.
CELL-SORTING STRATEGIES TO ISOLATE SSCS AND REMOVE MALIGNANT CONTAMINATION
There are legitimate concerns about malignant contamination of preserved testicular tissue, especially from leukemia patients (84, 85) . Several groups have demonstrated that it is feasible to isolate germ cells and remove malignant contamination from heterogeneous testicular cell suspensions using a fluorescence-activated cell sorter (FACS) and combinations of germ cell and/or cancer cell markers (86) (87) (88) (89) (90) . Despite these encouraging results, caution is warranted because even low levels of contamination can lead to cancer and current assays may lack the sensitivity to detect very rare malignant cells (85, 91) . Therefore, alternative methods for decontamination and screening as well as methods that do not require transplantation should be considered in some cases.
TESTICULAR TISSUE GRAFTING
In contrast to SSC transplantation, which involves disaggregation of SSCs from their cognate niches, testicular tissue grafting and testicular tissue organ culture (next section) maintain the integrity of the stem cell/niche unit. Honaramooz and coworkers demonstrated that testicular tissues obtained from newborn mice, pigs, and goats could produce complete spermatogenesis when grafted under the skin of nude mice (92) and later reported the production of offspring from sperm obtained after ectopic (under the skin) grafting of mouse testicular tissue (93) . Testis tissue from prepubertal rhesus macaques also produced complete spermatogenesis with fertilization-competent sperm after ectopic xenografting into nude mice (94) . Survival and spermatogenesis from adult testicular tissue grafts have been less successful than immature grafts (95) .
Cryopreservation is an essential component of the fertility preservation paradigm. Jahnukainen and coworkers evaluated several cryopreservation strategies with immature monkey tissues and found that freezing in 1.4 M DMSO provided good graft survival and spermatogenic induction up to the spermatocyte stage (96) . However, haploid germ cells were not produced in any grafts from that study, fresh or frozen. Wistuba and colleagues performed autologous testicular grafting in two studies in marmoset monkeys (97, 98) and reported that complete spermatogenesis was obtained in orthotopic (in the scrotum) but not ectopic grafts. Frozen and thawed tissues were also grafted in that study, but these were only transplanted ectopically and did not produce spermatogenesis (98) . Therefore, the question of whether frozen and thawed grafts can produce fertilizationcompetent haploid germ cells still needs to be addressed.
Several groups have reported xenografting of human testicular tissue to nude mice, and so far none have observed complete spermatogenesis or haploid gametes (99) (100) (101) (102) (103) (104) . In general, testicular tissues xenografted from prepubertal or adolescent boys survived long term (4-12 months) (100, 101, 103, 104) , with a calculated 3.7% spermatogonial recovery rate after 6 months in one study (104) and three studies reporting spermatocytes as the most advanced stage of germ cell development between 6 and 12 months after transplantation (101, 103, 104) . Some of those tissues were already postpubertal and contained meiotic or postmeiotic cells at the time of transplant, so it is difficult to exclude the possibility that the spermatocytes or occasional spermatids that were observed had persisted from the time of transplant (101, 104) . Importantly, the study by Sato and colleagues (103) observed primary spermatocytes 1 year after xenografting of testicular tissue from a 3-month-old boy, which clearly did not contain spermatocytes before grafting. In contrast to prepubertal/adolescent tissues, xenografted adult testicular tissues regressed over time (99, 102) . Although the human-to-mouse xenografting results are somewhat discouraging, the results of the monkey studies cited above suggest that autologous transplantation may be an option if suitable cryopreservation conditions are developed. Similar to SSC transplantation, autologous grafting will be problematic in cases where malignant contamination of the testicular tissue is suspected. Xenografting of human testicular tissue into animals could circumvent this problem but is associated with additional concerns about xenobiotics and has been unsuccessful to date.
TESTICULAR TISSUE ORGAN CULTURE
Sato and colleagues (27, 105) demonstrated that haploid male germ cells from mice could be generated in testicular tissue organ culture, using a gas-liquid interface method that was originally devised to keep differentiated organs alive in vitro (106) . Testis tissue was obtained from 2.5-to 3.5-day-old mice that contained only undifferentiated germ cells, similar to prepubertal patients. Testicular tissue was minced into fragments (1-3 mm diameter) that were placed on an agarose gel that was half soaked in medium, such that the tissue was exposed to air and absorbed nutrients through the agarose. Haploid round spermatids or sperm were retrieved after 23 or 42 days in culture, respectively, and used to successfully fertilize mouse oocytes in vitro by round spermatid injection and ICSI. The resulting embryos were transferred to recipient females and generated live offspring with normal development to adulthood and normal fertility (27) . The investigators also maintained frozen and thawed testicular tissue pieces in organ culture and were able to generate sperm, but the fertilization potential of that sperm was not tested. If these results in mice can be translated to humans, testicular organ culture would circumvent the need to put tissues or cells back into the patient and may be a safe option for patients with malignancies that contaminate the testes.
GERM CELLS DERIVED FROM PLURIPOTENT STEM CELLS
For males who did not preserve sperm or SSCs before gonadotoxic treatment, generation of transplantable germ cells (primordial germ cells or SSCs) or haploid gametes from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been explored. The iPSC technology is especially exciting because it would theoretically allow patients with no germ cells in their testes to father genetically related children. The derivation of germ cells from pluripotent cells will be covered in more detail in other articles in this issue. Here we will state briefly that several groups have reported the generation of germ cells from nonhuman primate ESCs (32, 33) and human ESCs and/or iPSCs (22) (23) (24) (25) (26) , including evidence of rare haploid cells in some cases. These results are exciting and revolutionary but are challenged by the inability to test the function of the resulting germ cells in the human system. Therefore, safety and feasibility will need to be established in animal models. In 2011, Hayashi et al. showed that mouse ESCs and iPSCs can be induced to an epiblast-like cell that then gives rise to primordial germ cells when BMP4 was added to a culture medium (28) . The resulting germ cells were transplanted into the testes of infertile mice and generated spermatogenesis with sperm that were used to fertilize oocytes using ICSI. The resulting embryos were transferred to recipient females and gave rise to viable offspring. These promising results need to be replicated in other laboratories, and more research is needed before this technique can be translated to the clinic, as some of the offspring developed malignant tumors around their neck area (28) . For iPSC-based technologies, it will be important to understand the effects of reprogramming, culture, and differentiation on the genome and epigenome of in vitroderived germ cells compared with endogenous germ cells (107) .
EXPERIMENTAL METHODS TO TRACK AND QUANTIFY HUMAN GERM LINE STEM CELLS
Studies on human cells and/or tissues are a valuable stepping stone toward clinical translation. However, these studies are challenged by the limited experimental tools for quantifying human spermatogonia and testing their function. In animal studies, the most compelling experiments are those that demonstrate the ability of a test cell population to regenerate spermatogenesis and produce fertilization-competent sperm, embryos, and offspring. This is an unrealistic expectation for human studies because fertilization of human eggs and production of human embryos are not universally legal or fundable. Based on progress in animal models, human-tohuman SSC transplantation is likely to be feasible in the clinical setting, but this is not an option for the routine testing of spermatogenic potential in the laboratory setting. Therefore, experimental assessment of human germ line stem cell potential must rely on descriptive endpoints and xenotransplantation for functional testing.
Here we propose that reliable markers of human undifferentiated spermatogonia are those with expression limited to germ cells located on the basement membrane of human seminiferous tubules and that meet one or more of the following criteria: 1) confirmed expression in Adark and/or Apale spermatogonia; 2) co-expression with other established markers of human undifferentiated spermatogonia (e.g., PLZF) or 3) that exhibit colonizing activity in the human to nude mouse xenotransplantation assay (see next paragraph and Figure 4D ). Proteins that meet these criteria, based on personal experience and review of the literature, include PLZF, GFRa1, GPR125, SALL4, LIN28, PGP9.5, UTF1, FGFR3, EXOSC10, DSG2, CBL, SSEA4, CD9, OCT2, and SSX (77, 78, (108) (109) (110) (111) (112) (113) (114) (115) (116) . Examples of PLZF, SALL4, and PGP9.5 expression in the seminiferous tubules of adult human testes are shown in Figure 4A -4C (Valli and Orwig, unpublished data).
In rodents, SSC transplantation is the gold standard that allows investigators to quantify germ-line stem cells by observing their biological potential to produce and maintain spermatogenesis in infertile recipient animals. At present, human-to-nude mouse xenotransplantation is the best functional assay to test the SSC-like potential of a test cell population (21, 38, 78, 89, 109, 115, 117) . This method does not recapitulate complete spermatogenesis from transplanted cells like mouse-to-mouse SSC transplantation, probably owing to the evolutionary distance between humans and mice. However, human-to-nude mouse xenotransplantation does assay the ability of transplanted cells to migrate to the basement membrane of seminiferous tubules, proliferate to produce characteristic colonies of spermatogonia, and persist long term as shown in Figure 4D (78, 89, 109, 115, 117 ).
CONCLUSION
The assisted reproduction field is on the verge of a renaissance, which is fueled in part by exciting developments that merge new stem cell technologies with fertile outcomes. Thus, it is reasonable to expect in the next decade that the options to preserve and restore male fertility will expand from sperm freezing followed by IVF/ICSI to also include stem cell transplantation, tissue grafting, and/or culture to produce fertilization-competent gametes ( Fig. 1 and Table 1 ). As with any rapidly developing field that has the potential to impact the clinic, it is essential to establish strict criteria to monitor progress and avoid sensationalism. Responsible technology development should ideally include [1] studies in lower mammals (e.g., rodents and other domestic species) where it is possible to examine functional readouts such as regeneration of spermatogenesis, fertilization, embryo development, and generation of healthy offspring. [2] As technologies mature, preclinical studies in nonhuman primates that have anatomy and reproductive physiology similar to humans will demonstrate conservation of biological concepts and facilitate optimization of technical/surgical approaches (e.g., biopsy, cell processing, freezing, and transplantation). Nonhuman primate studies are also amenable to functional assessments, although it is recognized that such studies will be limited to institutions with space, knowledge, and technical expertise for research in primates and specifically primate assisted reproductive technology. [3] Direct investigations of human cells or tissues are particularly valuable on the road to clinical translation but are challenged by the limited availability of human samples, study-to-study variation in sample quantity and quality, and the limited functional assays to assess experimental outcomes. Despite these challenges, human tissue studies to optimize tissue and cell-processing procedures, cryopreservation methods, and cell/tissue culture conditions will be the most relevant to the clinics that are already preserving testicular tissue for patients. Although it is not popular in the current era, descriptive studies of human germ lineage development in situ are essential to guide experimental design and interpretation of results of human stem cell studies.
Clinics worldwide are preserving testicular tissue for patients who do not have sperm in anticipation that new male fertility technologies will be available in the future. Each technology described in this review has merits and limitations that are detailed in the sections above. Owing to uncertainty about which methods will ultimately be translated to the clinic, it seems reasonable to preserve intact testicular tissue fragments in a way that maximizes viability after freezing and thawing (an active focus of research in many laboratories) and will be amenable to tissue-or cell-based approaches in the future. Variability in patient circumstances and reproductive goals dictate the parallel development of multiple technologies for preserving and restoring male fertility.
FIGURE 4
Experimental techniques to assay human spermatogonia. (A, B, and C) Expression of spermatogonia markers PLZF (A), SALL4 (B), and PGP9.5 (C) is limited to germ cells located on the basement membrane of human seminiferous tubules. Thus, they are reliable markers to screen test cell populations for human spermatogonia. DAPI (blue) stains all cell nuclei. Scale bar ¼ 50 mm. (D) Human-to-nude mouse xenotransplantation assay. Human testicular tissue is made into a cell suspension and then transplanted into the testis of busulfan-treated infertile nude mice. Two months after the transplantation, the testes are recovered, the tunica is removed, and the seminiferous tubules are gently dispersed to make a whole mount. The tubules are then stained with antiprimate antibody (122) to recognize the colonies of human spermatogonia (green). 
INTRODUCTION
Successful sexual reproduction will be essential for the continuity of the human race. However, infertility affects 15%-25% of couples of reproductive age [1, 2] . Evidence is increasing that the quality and quantity of germ cells produced by both men and women have declined over the past two decades due to myriad genetic [3, 4] and environmental causes [5, 6] . The advent of in vitro fertilization and other assisted reproductive techniques has helped infertile couples to parent their own children [7] ; however, nearly 10% of couples are still unable to have children due to a complete lack of germ cells [8] . Although infertility by itself may not threaten affected couples' physical health, it may lead to serious declines in social well-being [9] .
Stem cells are a class of undifferentiated cells that have the unique ability to self-renew and differentiate into specialized cell types. The potential for using stem cells to produce new tissues or repair damaged tissues has largely spurred the currently recognized field of regenerative medicine. Stem cells are categorized by their differentiation potential, with the full classification including totipotent, pluripotent, multipotent, oligopotent, and unipotent [10] . Generally, embryonic stem cells (ESCs) and the newly found induced pluripotent stem cells (iPSCs) [11, 12] are considered to be pluripotent because they have the ability to differentiate into most known embryonic and adult cell lineages. Stem cell niches provide microenvironments that maintain stem cells in an undifferentiated state, which supports their self-renewal by blocking differentiation signals. Moreover, tissue-specific signals emanating from the niche not only support self-renewal of stem cells occupying a given niche but also redirect the fate of early differentiating progenitor cells back into a stem cell state [13, 14] .
Mammalian germ cell lineages begin with primordial germ cells (PGCs), which generate spermatozoa and oocytes in suitable microenvironments provided by the male and female gonads, respectively. Based on the potential of pluripotent stem cells to generate embryonic lineages, including to the germline, many researchers have recently developed strategies to generate germ cells from pluripotent stem cells in vitro (Fig.  1) . Subsequently, artificial germ cells generated from nonpluripotent stem cells, such as somatic stem cells, have been reported. These approaches may offer us clues to understand the basic biology of gametogenesis, which holds the potential to open new avenues for treating or curing human infertility. In this review, we discuss historical studies to the most recent advancements in the generation of germ cells using embryonic and nonembryonic stem cells.
GERM CELL DERIVATION STRATEGIES AND PLAT-FORMS
To date, several different strategies are available for deriving gamete-like cells from stem cells in culture: 1) spontaneous differentiation, 2) differentiation in conditioned medium from somatic cells and/or coculture with somatic cells in medium supplemented with defined growth factors, 3) genetic manipulation, and 4) niche reprogramming ( Fig. 2A) .
Based on factors known to regulate sex determination, germ cell development, and pluripotent stem cell differentiation, systems for monitoring artificial germ cell development from ZENG ET AL. pluripotent cell lines have been explored using vital markers expressed under control of germline-restricted reporter genes (i.e., green fluorescent protein [GFP] under the control of germ cell specific promoters). The Mvh-Venus/GFP [15, 16] , Stella-GFP [17] , and Acr/Gsg2-GFP [18] reporters have been applied in such studies to visualize and sort out in vitro-derived germ cells. Moreover, signaling molecules, such as bone morphogenetic protein (BMP) 4 [19] , WNT3A [20] , and retinoic acid [21] have been identified as key factors responsible for deriving the induction of pluripotent stem cells into germ cell precursors.
Previous studies have already demonstrated that neonatal mouse testicular architecture can be reconstructed in the subcutis of nude mice [22] [23] [24] [25] , and development of functional germ cells has been reported. Importantly, using the gas-liquid interphase organ culture method, it has been convincingly demonstrated that functional sperm can be generated in vitro [26] [27] [28] and within spontaneously reconstructed epithelium from immature testicular cells [29] . Therefore, organ culture is becoming a useful platform for research associated with gametogenesis and could potentially be refined for artificial germ cell generation from accessible cell sources.
GERM CELL DIFFERENTIATION FROM SOMATIC STEM CELLS
Immunologic and genetic issues are primary challenges of stem cell-based therapeutic approaches and are important to consider in artificial germ cell generation. Fortunately, derivation of autologous stem cells will open new avenues for generating immunocompatible artificial germ cells (Fig. 1) . Some evidence has shown that germ-like cells can be generated from somatic stem cells derived from mouse [30, 31] , sheep [32, 33] , or human [34] [35] [36] mesenchymal stem cells; fetal mouse skin [37, 38] as well as porcine skin [39] [40] [41] [42] or muscle [42, 43] stem cells; and human amniotic fluid stem cells [44, 45] . Combined, these studies provide examples in which somatic stem cells differentiated into male or female germ cells in culture. Although these presumptive germ cells expressed germ cell-related markers, they did not progress beyond the early stages of germ cell development, even after transplantation into the testis or ovaries. Thus, research on artificial germ cell generation directly from adult somatic stem cells is far from being optimized.
GERM CELL DIFFERENTIATION FROM GERMLINE STEM CELLS
In mammals, the germline is unique because it is the only cell lineage that undergoes cell division of two types, mitosis and meiosis, as a requisite for forming haploid gametes. The general developmental steps in gametogenesis for production of sperm or eggs are largely elucidated. Moreover, germline stem cell (GSC) lines may become more suitable for artificial germ cell generation under appropriate culture conditions because sperm and eggs can develop from GSC lines (Fig. 1) . Recently, new evidence demonstrated that female GSCs (FGSCs) isolated from mouse [46] [47] [48] [49] , rat [50] , human [48, 49] , and pig [51] could generate viable offspring or differentiate into oocytes in vivo. Additionally, mouse FGSCs cultured in vitro can differentiate into oocyte-like cells [52] mediated by BMP4 signaling [53] . Although these newly found GSCs hold great potential for artificial oocyte production in vitro, support for the traditional view (i.e., no postnatal follicular renewal occurs in mammals) still exists. Lei and Spradling [54] concluded that adult mouse ovaries lack stem cells after they failed to detect ''germline cysts'' using a lineage tracing approach, and Zhang et al. [55] failed to get mitotically active female germline progenitors from postnatal mouse ovaries. However, as Bhartiya et al. [56] suggested, absence of evidence is not necessarily the evidence of absence. No matter what the various opinions on FGSC, extensive collaborations from different labs supporting the evidence for and against FGSC in mammals should be carried out to address these issues, and many other problems also need to be solved. These include more specific FGSC marker analysis, more efficient isolation and purification protocols, culture condition optimization, stronger lineage tracing studies, and elucidation of the signaling pathways driving FGSC differentiation in vivo. More importantly, it remains to be determined if oocyte-like cells differentiated from FGSCs in vitro maintain the capacity for fertilization with sperm. Likewise, roles for FGSCs in oogenesis, menopause, and even ovarian-related disease remain to be determined.
As the other gender of GSCs, spermatogonial stem cells (SSCs) in testes have been widely studied. Still, in vitro spermatogenesis in mammals has only been reported by one group [57] . It should be noted that the presumptive SSCs from that study were ''experimentally immortalized,'' and similar studies have yet to be performed by other laboratories. Thus, unmodified SSCs are still difficult to differentiate into haploid gametes in vitro. Although some studies have shown that SSCs could support spermatogenesis and then differentiate into functional sperm using seminiferous tubule transplantation and organ culture (standard gas-liquid interphase method) in vitro [18, [58] [59] [60] , such protocols are still complex and difficult to perform. Interestingly, other three-dimensional (3D) in vitro culture systems using two different matrices (soft agar and methylcellulose) reveal the potential for artificial germ cell generation [61, 62] . A new report has shown that mouse male SSCs can be converted into oocyte-like cells in culture [63] , but whether the FGSCs can be converted into spermatogenic cells is still unknown.
It should be stressed that almost all of the artificial or presumptive germ-like cells reported in this review have not resulted in robust, reproducible protocols for deriving gametes, much less approached the gold standard of demonstrating the capacity to produce healthy offspring by fertilization [2] . A major problem in the field is that conventional techniques used for presumptive germ cell identification often lead investigators down incorrect paths due to false positives generated by 1) PCR marker analysis (caused by cell preparation and/or genotyping sample contamination or by misleading pseudogene or retrogene detection), 2) antibody labeling artifacts/ nonspecific signals, and 3) subjective gating/thresholding to analyze DNA content.
GERM CELL GENERATION FROM PLURIPOTENT STEM CELLS
Steady progress has been made in the generation of germ cells from pluripotent ESCs or iPSCs (Fig. 1) .
Germ Cells Differentiated from ESCs
In mice, the first evidence of germ cell generation from ESCs was provided by Hubner et al. [64] . They found that mouse ESCs (mESCs; both XX and XY chromosomes) tagged by Oct4-GFP in the absence of feeder cells and added growth factors condition spontaneously and differentiate into presumptive oocyte-like cells, which not only coexpress oocytespecific markers (SCP3, ZP2, and ZP3) but also form folliclelike structures. Interestingly, these putative oocytes could even develop into blastocyst-like structures via subsequent parthe-ARTIFICIAL GERM CELL GENERATION FROM STEM CELLS nogenic activation. Toyooka et al. [19] found that mESCs could be induced into Mvh-GFP-positive and/or Mvh-lacZpositive cells via embryoid body (EB) differentiation or coculture with somatic cells expressing BMP4. The flowsorted Mvh-postive cells could participate in spermatogenesis in vivo after transplantation into host testis; however, spermatozoa produced were not tested for fertility. Geijsen et al. [65] and West et al. [66] then described haploid gametes generated from ESC differentiation that were competent to form blastocysts following injection into oocytes. Another study showed that oocyte-like cells could be derived from mESCs with XY chromosomes when cultured in conditioned medium collected from testes of newborn male mice [67] . Meiotic progression of germ-like cells were reportedly derived in vitro from mouse and human pluripotent cell lines (ESCs and iPSCs) by ectopic expression of germ cell-specific or meiosis-related proteins, including DAZ [68, 69] , DAZL [68] [69] [70] [71] , BOULE [68, 69] , DDX4 [71] , and GASZ [72] .
Although these studies have suggested that mESCs can differentiate into female and male germ cells in vitro, the differentiation strategies employed were complex, inefficient, and differed substantially among the respective laboratories. It remains to be determined if germ-like cells generated from pluripotent stem cell lines by such approaches are capable of generating offspring. This breakthrough was provided by Nayernia et al. [73] , who demonstrated the birth of live offspring from mESC-derived sperm-like cells. They used a dual fluorescent reporter system (Stra8-driven GFP reporter and Prm1-driven DsRed reporter) to track the progression of mESC-derived germ cells during their derivation process. Cells with sperm-like characteristics were isolated by fluorescenceactivated cell sorting and then injected into mouse oocytes that developed into live offspring. There have been many attempts (Table 1) using different approaches to allow germ-like cells to progress into or complete meiosis. However, several groups [74, 75] have reported that germ-like cells derived from ESCs fail to progress through meiosis appropriately.
Germ cell derivation from cynomolgus monkey ESCs [76, 77] and human ESCs (hESCs) is also being rigorously investigated [78] . In one approach, hESCs were differentiated into germ-like cells using a 3D coculture system based on calcium alginate encapsulation of the ESCs with testicular somatic cells [79] . Although germline-specific markers were clearly expressed by primate cells derived in these systems, functional assays for testing successful generation of human artificial germ cells are largely lacking.
Germ Cells Differentiated from iPSCs
Despite ethical issues centered on germ cell derivation from pluripotent stem cell lines in culture [80] , iPSC technology holds tremendous potential for generating patient-specific artificial gametes. Studies reporting that male hESCs and human iPSCs (hiPSCs) can be differentiated into haploid spermatogenic cells in culture have achieved two significant endpoints: artificial generation of adult-type spermatogonia and postmeiotic round spermatids [81] . However, it remains unknown whether these haploid cells are functional. Proofof-concept for these studies is provided by recent breakthroughs demonstrating the germ cell differentiation potential of iPSCs by Saitou's group. First, male (XY) mESCs and iPSCs bearing Prdm1-mVenus and DPPa3-ECFP (BVSC) reporters were induced into epiblast-like cells (EpiLCs) [82, 83] and then further into PGC-like cells (PGCLCs), which differentiated into viable spermatozoa in recipient mice that were able to generate healthy offspring [84] . Next, to determine whether their reconstitution strategy could be translated to oocyte production, female ESCs and iPSCs expressing BVSC transgenes were induced into EpiLCs and then further into PGCLCs via a differentiation pathway similar to that in males, followed by aggregation with embryonic gonadal somatic cells as in vitro. The PGCLCs underwent oogenesis, including Xreactivation, imprint erasure, cyst formation, and meiosis, after the reconstituted ovarian cells were transplanted under adult mouse ovarian bursa. Functional germinal vesicle oocytes were generated from PGCLCs in up to 1 mo but displayed some differences from normal oocytes, including abnormal elliptical shape at a higher frequency, and a subset of them failed to extrude the second polar bodies. The PGCLC-derived oocytes were matured into eggs in vitro and then contributed to healthy and fertile offspring after fertilization with spermatozoa [85, 86] . These results demonstrated that mESCs and iPSCs could be used for reconstituting the entire processes of spermatogenesis and oogenesis, which might provide the long-sought-after foundation for studying mammalian gametogenesis in vitro. Recently, Nakaki et al. [87] reported a refined strategy for mouse germ cell reconstitution that did not depend on a cocktail of added cytokines; rather, expression of transcription factors (Blimp1, Prdm14, and Tfap2c) in EpiLCs was sufficient to induce PGCLCs development that could further contribute to spermatozoon production and healthy offspring.
GERM CELL GENERATION FROM NICHE REPRO-GRAMMING
Gametogenesis is regulated by ovarian and testicular microenvironments that develop specialized cell-cell and growth factor interactions (nonstem and stem cells), or niches. Therefore, generation of germ cells from stem cells in vitro may likewise require complex niches, including appropriate hormones (endocrine and paracrine), extracellular matrix architecture, and other environmental factors.
Durruthy Durruthy et al. [88] reported that undifferentiated hiPSCs derived from mRNA-based reprogramming with OSKM (OCT3/4, SOX2, KLF4, and cMYC) or OSKMV (OSKM plus a germ cell-specific marker, VASA) factors could directly differentiate into germ cells after transplantation into the seminiferous tubules of germ cell-depleted immunodeficient mice. Significantly, the OSKMV-based iPSCs did not form tumors, whereas the OSKM-based iPSCs that remained outside the seminiferous tubule did. The same group also found that hESCs and azoospermia factor (AZF)-deleted hiPSCs inside murine seminiferous tubules could receive critical molecular cues directing germline differentiation; however, outside seminiferous tubules, AZF-deleted iPSCs maintained their undifferentiated state and formed tumors [89] . Thus, these studies suggest that niche cells, potentially Sertoli cells, are critical to suppress somatic cell differentiation and favor the germline fate in hiPSCs.
CONCLUSIONS AND PERSPECTIVES
Complete restoration of gametogenesis in culture will be important to our understanding of biological events at the cellular and molecular levels that are important for germline development. Understanding these processes will have an enormous impact on applications in the biomedical and agricultural communities. The studies mentioned above suggest that artificial or in vitro-differentiated germ cells could be readily derived from stem cells, including somatic, germline, and pluripotent stem cells.
Significantly, without any gene delivery, unipotent SSCs from mouse [90] [91] [92] [93] [94] and human [95, 96] can convert into an ZENG ET AL. [97] . Importantly, FGSCs share many similar characteristics with SSCs [98, 99] , whereas a recent report shows that FGSCs can be converted into pluripotent stem cells similar to those of SSC conversion [100] . Thus, in theory, these female germline-derived pluripotent stem cells should have ability to differentiate back into germ cells. These studies suggest not only that gESLCs may be used for germ cell derivation in vitro (Fig. 1 ), but also that germ cell generation from the gESLC differentiation system provides a unique platform to dissect cellular and developmental mechanisms underlying gametogenesis. This platform may help us find new approaches to treat sex reversalassociated disease. Today, evidence is accumulating that somatic cells can be transdifferentiated into other cell types without acquiring a pluripotent state [101, 102] ; however, whether the somatic cells can directly transdifferentiate into spermatocytes or oocytes by ectopic expression of germline-specific transcription factors is unknown (Fig. 2B) . Additionally, the combination of niche reprogramming and newly found 3D printing techniques [103] may be useful for stem cell-based artificial germ cell generation.
Several problems remain to be solved before artificial germ cells can be applied for treating infertility. These include efficient and highly reproducible protocols for in vitro derivation of genetically and epigenetically healthy, patientspecific gametes from stem cells. Health status of such artificially generated germ cells could theoretically be diagnosed with markers on genome-wide levels (i.e., epigenome, transcriptome, proteome, and metabolome). Once these standards-and any additional safety and ethical standardsare surpassed, clinical application of artificially generated human gametes may someday be warranted for the purpose of treating relevant infertility cases. ZENG ET AL.
